Novartis reported Phase 3 results showing its combination therapy GanLum (ganaplacide plus lumefantrine) was non-inferior to standard of care in 1,688 patients across sub-Saharan African sites and met World Health Organization efficacy thresholds. One analysis reported cure rates as high as 97% at day 28, and the company signaled plans to seek regulatory approvals promptly. Ganaplacide attacks a parasite protein-transport system, a mechanism designed to overcome rising artemisinin resistance. Novartis ran the trial with Medicines for Malaria Venture partners across 12 countries, and the dataset included efficacy against resistant parasites and indications of reduced transmission. If regulators approve GanLum it would be the first novel antimalarial in more than two decades and could reshape frontline treatment in regions facing artemisinin failure.